Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc (GENFF) is a biotechnology company leading in longevity research, dedicated to developing therapeutic solutions for age-related diseases. Founded in 2020, Genflow is headquartered in the UK with R&D facilities in Belgium. The company's focus is on pioneering gene therapies to slow down the aging process, aiming to extend healthy lifespans and address the challenges posed by an aging global population. Genflow's flagship product, GF-1002, delivers a centenarian variant of the SIRT6 gene, showing promising preclinical outcomes. In 2025, Genflow will launch clinical trials to test GF-1002's potential in treating MASH, the most common chronic liver disease with no existing effective treatments.
Genflow Biosciences has announced the receipt of €381,434, which is 50% of a research grant from the Government of Wallonia in Belgium. This non-diluting and non-reimbursable grant will fund Genflow's sarcopenia research project over the next three years, conducted in partnership with Revatis SA. The project focuses on developing muscle progenitor cells (MPCs) loaded with Genflow's proprietary SIRT6 gene to prevent and treat sarcopenia. The remaining grant amount will be disbursed over the next two years based on submitted invoices. The goal is to enhance muscle regeneration and improve the quality of life for older adults affected by muscle loss.
Genflow Biosciences PLC disclosed a major holding by Jonathan Mark Swann, increasing the voting rights to 5.03% with 17,586,000 shares on May 9th, 2024. The London-based company received the notification on May 10th, 2024. The disclosure follows the standard TR-1 form for major holdings. The shareholder, Jonathan Mark Swann, is based in Rickmansworth, United Kingdom.
Genflow Biosciences Plc, a leader in longevity research, announces the restoration of its listing on the London Stock Exchange after publishing its FY23 Results. The Company's ordinary shares are set to be relisted, marking a significant milestone in its financial journey.
Genflow Biosciences Plc, an emerging leader in longevity research, announces its final results for the year ended 31 December 2023. The company focuses on developing therapeutic solutions for age-related diseases. Genflow is the first longevity biotechnology company listed in Europe.
Genflow Biosciences PLC announces a temporary suspension of listing due to delays in publishing its Annual Financial Report for the financial year ending on December 31, 2023. The delay is not related to the company's financial position. The listing of the company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended from May 1, 2024.
Genflow Biosciences PLC, a leader in longevity research, disclosed its total voting rights on April 30, 2024. The company's total issued share capital consists of 349,706,618 Ordinary Shares with no shares held in treasury, resulting in the same number of voting rights. Shareholders can use this figure to determine their disclosure obligations under the Financial Conduct Authority's rules.
FAQ
What is the current stock price of Genflow Biosciences (GENFF)?
What is the market cap of Genflow Biosciences (GENFF)?
When was Genflow Biosciences Plc founded?
Where is Genflow Biosciences Plc headquartered?
What is the primary focus of Genflow Biosciences Plc?
What is GF-1002?
What disease does Genflow Biosciences Plc aim to treat with GF-1002?
What is the research focus of Genflow Biosciences Plc?
What recent grant funding has Genflow Biosciences Plc received?
When will Genflow Biosciences Plc start its clinical trial for GF-1002?
